Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
Federico BaroneAndrea GiacomelliGiacomo CasaliniMario CorbellinoAlessia LaiAndrea GoriSpinello AntinoriPublished in: The Journal of antimicrobial chemotherapy (2024)